GENESTITCH
LIVE

Serial Number

99393442

Owner

Weaver Biosciences, Inc.

Attorney

Christina M. Licursi

Filing Date

Sep 15, 2025

Add to watchlist:

No watchlists yet
View on USPTO

GENESTITCH Trademark

Serial Number: 99393442

GENESTITCH is a trademark filed by Weaver Biosciences, Inc. on September 15, 2025. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Weaver Biosciences, Inc. (2 trademarks)

800 Boylston Street, Suite 1715
Boston, MA 02199

Entity Type: 03

Trademark Details

Filing Date

September 15, 2025

Registration Date

Not Registered

Goods & Services

Biological preparations for use in industry and science and chemical agents for use in industry and science; biological preparations comprising of small molecules for use in scientific research; bacterial and viral substances other than for medical and veterinary uses; chemicals and biological chemical preparations for use in medical science, namely, for use in biochemical and clinical research

Scientific research and pharmaceutical development services; development of gene-based medicines; medical and scientific research in the fields of genetics, genomics, gene modulation and genetic engineering; DNA and RNA analysis and sequencing services for scientific and research purposes; research, development and scientific consultancy in the field of genomics and gene modulation; scientific research in the field of biology, molecular biology, cell biology, biotechnology, bacteriology, immunology, genetics, medicine, pharmacology, virology, chemistry, scientific research of vaccines, and antibiotics; providing online non-downloadable software using artificial intelligence, computational methods, and machine learning models for data analysis in the fields of disease, biomedical, and genomic research; providing online non-downloadable software using artificial intelligence, computational methods, and machine learning models for the design and characterization of therapeutic products and drug analysis in the field of drug discovery and development; providing online non-downloadable software using artificial intelligence and machine learning models for collecting, analyzing, assessing, interpreting and predicting medical, health, transcriptional, genetic, genomic, pharmacogenomic, molecular, biochemical, and biomarker information, associations, conditions, outcomes, effects and risks

Pharmaceutical preparations and therapeutic pharmaceuticals for the treatment of cancer, immune system diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, neurological diseases and disorders, respiratory diseases and disorders, infectious diseases and disorders, dermatological diseases and disorders, ophthalmological diseases and disorders, hematological diseases and disorders, and gastroenterological diseases and disorders

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 11, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 19, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 19, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 19, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 18, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 18, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 18, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 9, 2026 GNRN
NON-FINAL ACTION E-MAILED
Feb 9, 2026 GNRT
NON-FINAL ACTION WRITTEN
Feb 9, 2026 CNRT
ASSIGNED TO EXAMINER
Feb 9, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 6, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Sep 15, 2025 MAFR
NEW APPLICATION ENTERED
Sep 15, 2025 NWAP